Zealand Pharma A/S ( (ZLDPF) ) has released its Q3 earnings. Here is a breakdown of the information Zealand Pharma A/S presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Zealand Pharma A/S is a biotechnology company based in Copenhagen, Denmark, specializing in the discovery and development of peptide-based medicines, with a focus on obesity and rare diseases.
In its latest earnings report for the first nine months of 2025, Zealand Pharma highlighted significant progress in its clinical trials, particularly with petrelintide and survodutide, which are advancing towards key data readouts in 2026. The company also announced a strong financial performance, driven by a substantial upfront payment from its partnership with Roche.
The company’s financial results showed a remarkable increase in revenue to DKK 9.1 billion, primarily due to the collaboration with Roche. Zealand Pharma’s operating expenses were largely attributed to the advancement of its obesity pipeline, including the Phase 2 trials for petrelintide. The company maintains a solid cash position of DKK 16.2 billion, enabling continued investment in its research and development efforts.
Looking ahead, Zealand Pharma is poised for a catalyst-rich 2026, with upcoming data readouts for its leading drug candidates and plans to outline its ambitious research strategy at the Capital Markets Day in December. The company’s focus remains on leveraging its expertise in peptide R&D to drive innovation in obesity treatment.